Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05409183 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of CRD-740 in Heart Failure
A Phase 2 study, sponsored by Cardurion Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT05409183: Clinical Trial Phase 2 study, sponsored by Cardurion Pharmaceuticals.
NCT05409183 is a Phase 2 study that was terminated before completion, run by Cardurion Pharmaceuticals. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05409183, a Phase 2 study, was terminated before completion, sponsored by Cardurion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is a study evaluating the effectiveness of CRD-740 in patients with either Heart Failure with Reduced Ejection Fraction (HFrEF) or Heart Failure with Preserved Ejection Fraction (HFpEF) after 12 weeks of treatment. The primary objective in Part A is to assess the effect of CRD-740 compared to placebo in plasma cGMP at Week 4 in HFrEF. Part B of the study was not conducted in favor of redesigned new studies.
Primary Outcome
Efficacy: To assess the effect of CRD-740 compared to placebo in plasma cGMP at Week 4 in subjects with CHFrEF.
Interventions
- DRUG Placebo
- DRUG CRD-740
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-05-26 |
| Est. Completion | 2023-07-25 |
| Phase | Phase 2 |
Why NCT05409183 stopped before completion
NCT05409183 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05409183 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05409183 about?
NCT05409183 is a clinical study titled "Effectiveness of CRD-740 in Heart Failure". This is a study evaluating the effectiveness of CRD-740 in patients with either Heart Failure with Reduced Ejection Fraction (HFrEF) or Heart Failure with Preserved Ejection Fraction (HFpEF) after 12 weeks of treatment. The primary objective in Part A is to assess the effect of CRD-740 compared to p...
What is the current status of trial NCT05409183?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2022-05-26. Estimated completion is 2023-07-25.
What interventions are being tested in trial NCT05409183?
The interventions under investigation include: Placebo (DRUG), CRD-740 (DRUG).
Who is sponsoring clinical trial NCT05409183?
This trial is sponsored by Cardurion Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05409183's enrollment target sits among peer trials
60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI